Thresholds and endocrine disruptors: An Endocrine Society Policy Perspective

Barbara Demeneix 1, Laura N. Vandenberg 2, Richard Ivell 3, R. Thomas Zoeller 4

1 Emeritus Professor, UMR 7221, CNRS, Muséum National D’histoire Naturelle, Paris, France
2 Associate Professor, School of Public Health and Health Sciences, University of Massachusetts Amherst, USA
3 Special Professor, School of Biosciences, University of Nottingham, UK
4 Professor Emeritus of Biology, University of Massachusetts Amherst and Visiting Professor, Örebro University, Örebro Sweden.

Corresponding Author: R. Thomas Zoeller, Biology Department, University of Massachusetts Amherst, 611 N Pleasant St., Amherst, MA 01003. tzoeller@bio.umass.edu

© Endocrine Society 2020. js.2020-00223
https://academic.oup.com/endocrinesociety/pages/Author_Guidelines for Accepted Manuscript disclaimer and additional information.
This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
Abstract

The concept of a threshold of adversity in toxicology is neither provable nor disprovable. As such, it is not a scientific question but a theoretical one. Yet, the belief in thresholds has led to traditional ways of interpreting data derived from regulatory guideline studies of the toxicity of chemicals. This includes, for example, the use of standard “uncertainty factors” when a “No Adverse Effect Level” (or similar “benchmark dose”) is either observed, or not observed. In the context of Endocrine Disrupting Chemicals (EDCs), this approach is demonstrably inappropriate. First, the efficacy of a hormone on different endpoints can vary by several orders of magnitude. This feature of hormone action also applies to EDCs that can interfere with that hormone. For this reason, we argue that the choice of endpoint for use in regulation is critical, but note that guideline studies were not designed with this in mind. Moreover, the biological events controlled by hormones in development not only change as development proceeds but are different from events controlled by hormones in the adult. Again, guideline endpoints were also not designed with this in mind, especially since the events controlled by hormones can be both temporally and spatially specific. The Endocrine Society has laid out this logic over several years and in several publications. Rather than being extreme views, they represent what is known about hormones and the chemicals that can interfere with them.
In a commentary recently published in Critical Reviews in Toxicology (1), Dr. Susy Brescia lays out the logic to support a “risk-based” approach to regulating endocrine disrupting chemicals (EDCs). Key to this approach is the assumption of a threshold of adversity. We, as members of the Endocrine Society’s Endocrine Disrupting Chemicals (EDC) Advisory Group, would like to address a few key scientific issues.

1. **Thresholds of adversity.** Key to risk assessment is the identification of a “threshold of adversity” e.g., the highest dose that does not produce an observable effect on a chosen endpoint. But, the choice of endpoint is key. For example, the concentration of lead required to affect measures of cognitive function in children is far less than the lethal dose in adults (e.g.,(2,3)) Since regulators initially developed safety determinations for lead exposures based on morbidity and lethality in adults, millions of children were harmed.

Lead toxicity presents another challenge: what should be done when no safe level of exposure can be identified (4-6)? This point could not be made any clearer than the US CDC’s 2012 report on childhood lead poisoning prevention, which states, “new studies and re-interpretation of past studies have demonstrated that it is not possible to determine a threshold below which [blood lead level] is not inversely related to IQ” and “It is now clear that there is no known threshold below which adverse effects of lead are absent” (7). In this case, it can be argued that a threshold for the effect of lead on brain development and IQ could exist, but one has not been demonstrated empirically. Given that the estimated “safe” level of chemical exposure often decreases as new data become available, it is clear that the early estimates of safety are often insufficient to protect human health (8).
Lead is not alone in its ability to have effects at even very low levels of exposure (9-13). Unfortunately, documented “low dose effects” exist for dozens if not hundreds of chemicals, including EDCs. Despite the fact that human exposures are “low”, below the levels that cause mortality or other overt signs of toxicity in laboratory animals, epidemiological studies continue to document associations between EDCs and human disease outcomes in a manner that is concordant with mechanistic studies (14-22). For EDCs, this reality was acknowledged in a 2017 report by the US National Academy of Sciences (23), which provided recommendations on how the Environmental Protection Agency should conduct investigations for low dose effects of EDCs in a regulatory context.

In addition, as professors Demeneix and Slama state in a report for the European Parliament (24), approaches used in regulatory toxicology still do not take into account the effects of chemical mixtures that impinge on the same endocrine signaling pathways or on interacting hormones (25). All children are exposed both prenatally (26) and postnatally (27) to multiple xenobiotics, many of which have the potential to interfere with the endocrine system. This emphasizes the need for caution in the use of thresholds focused on individual chemicals.

During a consensus meeting that included regulators, toxicologists, epidemiologists and endocrinologists, a consensus was reached on a series of scientific principles to identify EDCs (28). It was agreed that the concept of thresholds should be further researched. The statement on this point concludes “that it may be difficult to distinguish a true threshold from an apparent threshold which merely arises from the limits of detection of the experimental system. Thus, the question of the existence of dose-thresholds for endocrine disruptors cannot be resolved through empirical dose-response studies alone but has to rely on mechanistic investigations and increased knowledge on the functions and programming of the endocrine system during specific windows of sensitivity.” Moreover, given that the estimated “safe” level of chemical exposure is often decreased as new data
become available, the early estimates including uncertainty factors demonstrate that estimates of the true or practical threshold were overestimated (8).

Furthermore, there are several additional reasons why the validated endpoints employed in OECD guidelines may fail to provide clear information about whether or not a “threshold” exists. First, there is the sensitivity of the biological outcomes evaluated. For example, the uterotrophic assay focuses on organ weight, even though many endocrine disrupting effects do not entail any change in the overall organ weight (see (29) for an example). Second, the variability in results obtained in studies such as the uterotrophic assay depends on protocol differences, all permitted within validated guidelines, including the use of rats or mice and their different strains, or injection versus gavage (30). Third, there is the assumption of a monotonic dose response in regulatory testing that influences all aspects of study design; monotonicity is an unlikely default assumption for most EDCs (13).

The commentary concludes that, “A threshold approach to the risk assessment of [EDCs] is scientifically justified.” However, it can only be justified if you ignore that endpoints of adversity in standard toxicological studies are not sensitive to EDCs (31,32), that uncertainty factors often overestimate the theoretical threshold, and that mixture effects are not considered.

2. **Hormones and development.** (Brescia, 2020) also makes the statement that it is an “extreme position” to hold that the developing organism has “homeostatic mechanisms [that] are not sufficiently developed such that a threshold of adversity cannot be assumed for EDCs acting during the developmental stages of the life cycle”. The commentary further states that this position is “not supported by decades of observations and safety testing of developmental toxicants, with little evidence
suggesting that the fundamental rules governing endocrine function cease to apply during this life stage…”.

To be clear, framing the position of the Endocrine Society (33) as “extreme” throws into sharp relief the difference between the author’s perception of regulatory toxicology and that of fundamental science. The Endocrine Society is the largest and oldest society of clinicians and scientists focused on understanding hormone systems in health and disease. It has more than 18,000 members and was founded over 100 years ago. We are further concerned about the juxtaposition in the article of the consensus position of a longstanding medical and scientific society with commentary from industry consultants.

Moreover, use of the term “endocrine function” in the statement above is ambiguous. Because the human fetus does not have a functional thyroid gland during the first trimester of development despite having a requirement for thyroid hormone for normal development during this period (34,35), “endocrine function” obviously changes through development. Perhaps instead what (Brescia, 2020) refers to is “endocrine action”. Clearly we are well aware that the fundamental rules of endocrine actions are the same throughout the life cycle (e.g., (36,37)). Rather than being an extreme view (33), it is uniformly held by scientific societies that fetal development represents a very complex time of hormone action. Thus, the downstream actions of hormones are often quite different during development compared to the adult, the sensitivity of the fetus to the same hormone is often much greater during development, and the effects downstream of hormone action are often not reversible (38-41).

The crux of our perspective, supported by decades of endocrine science, is that if a chemical interferes with the action of a specific hormone, the effects of exposure will be consistent with those actions. For example, an antiandrogenic chemical exposure during fetal development would interfere with testosterone action (e.g.) in the brain and produce effects that in some cases would not be observed until adulthood (32). Moreover, because the developing brain is very sensitive to testosterone, the dose at which an antiandrogenic
chemical would produce adverse effects in the fetus would be lower than those required to interfere with testosterone actions in the adult.

We specifically note that many of the adverse outcomes of EDCs are not evaluated in standard regulatory toxicology testing, such as altered neurite outgrowth, neuronal migration, myelination (and more) in the brain following thyroid hormone disruption. Further, there is no guideline study that evaluates brain sexual dimorphisms, or sensitive social behaviors in rodents that have had alterations to these sensitive brain regions (42-44). While the US EPA defines an adverse neurodevelopmental effect as “an adverse change in the structure or function of the central and/or peripheral nervous system…”(45), there are no sensitive markers of these events in current test guidelines. Also, no regulatory toxicology tests exist that evaluate the impacts of environmental chemicals on mammary gland morphology or development, and the evaluation of outcomes relevant to breast cancer are recognized to be insufficient (46-49).

Even though the US EPA defines an adverse effect as “a biochemical change, functional impairment, or pathologic lesion that affects the performance of the whole organism, or reduces an organism’s ability to respond to an additional environmental challenge” [(50), emphasis added], there are no guideline studies that evaluate whether exposures to EDCs alter the response of animals to environmental stressors. Yet, numerous studies show that animals exposed to EDCs are more sensitive to hormones, carcinogens, allergens, and other environmental challenges [e.g., (51-54)]. The recognition of these weaknesses in EDC testing was the basis for a major effort in the European Union funded by Horizon 2020 to identify better endpoints that can be captured by OECD test guidelines (55). These are hardly “extreme” positions.

The suggestion that fetuses, neonates and infants have sufficient “homeostatic” functions to protect them from environmental pollutants is in fact an example of an “extreme” position that is not supported by evidence. There are numerous studies documenting that the fetal compartment acts as a depot for some chemicals including EDCs [e.g., perfluorinated...
compounds (56), polybrominated diphenyl ethers (57)]. Furthermore, regulatory toxicologists acknowledge the insufficiency of “homeostatic” functions at different life stages when using adjustment factors to account for “life stage” during risk assessments. Yet, even the standard default uncertainty factor of 10, which is typically used to acknowledge the increased vulnerability of fetuses, neonates, infants and children, is often insufficient; numerous studies provide evidence that individuals at these vulnerable stages of development are more than 10-times more sensitive than adults (58,59). This reality has also been acknowledged by regulators in the US (60).

Endocrinology is a scientific field that relies upon the theory of falsifiability (sometimes also referred to as the Popper framework). In our field of study, for a hypothesis to be credible, it must be disprovable. In contrast, (Brescia, 2020) describes a framework where the demonstration of a true threshold would “entail studying an infinite number of organisms of the species in question… using infinitely precise measures… and an infinite number of doses…” The author acknowledges that “Hypotheses regarding where on the dose-response curve the true threshold lies are beyond the ability of science to resolve” and is therefore not a scientific question.

The Endocrine Society holds that rigorous scientific evidence, including fundamental features of endocrinology, should inform safety determinations, even when these features challenge and force us to rethink conventional concepts in toxicology. Thus, it is essential to identify the threshold of empirical data required to identify safe levels of chemicals to which we expose the entire human population.
Acknowledgements:

The authors wish to thank Dr. Joe Laakso, director of science policy for the Endocrine Society and Dr. Shirlee Tan, toxicologist with Public Health – Seattle & King County for their careful review and comment on this commentary.

Disclosures & Disclaimers:

This letter was drafted in response to the commentary by Susy Brescia, “Thresholds of adversity and their applicability to endocrine disrupting chemicals”. This response is submitted by the authors (Barbara Demeneix, Laura Vandenberg, Richard Ivell, and R. Thomas Zoeller) on behalf of the Endocrine Society’s Endocrine Disrupting Chemicals Expert Advisory Group and the members of this Advisory Group.

The Endocrine Society’s EDC Advisory Group provides coordinated oversight and guidance on Society activities related to Endocrine Disrupting Chemicals (EDCs) covering all relevant Society functions, including publications, education, and policy. The EDC-related positions and priorities that the Endocrine Society advocates for are described in our Position Statement on EDCs (https://www.endocrine.org/advocacy/position-statements/endocrine-disrupting-chemicals) and Position Statement on EDCs in the EU (https://www.endocrine.org/advocacy/position-statements/endocrine-disrupting-chemicals-in-the-european-union).

None of the authors received funding from any source for this commentary. The views expressed here are the professional opinions of the authors and do not necessarily reflect those of their employers or any agencies that have funded their work. There are no contractual relations or proprietary considerations that restrict the authors’ publication or dissemination of the findings described in the manuscript.
Dr. Demeneix is currently the chair of the Endocrine Society’s EDC Advisory Group and is co-chair of one of its Task Force groups. Her EDC-related research has been funded by government and EU agencies and foundations. Dr. Demeneix holds a patent under the name “Transgenic clawed frog embryos and use thereof as detectors of endocrine disruptors in the environment” filed in 2002 (number FR020669) and extended by a Patent Cooperation Treaty filed in 2003.

Dr. Vandenberg is currently a member of the Endocrine Society’s EDC Advisory Group, is co-chair of one of its Task Force groups, and a member of two other Task Forces. She is also a member of the US EPA’s Science Advisory Board Chemical Assessment Advisory Committee and a scientific advisor (unpaid) to two Horizon 2020 EDC grants. Her travel has been sponsored by various government, academic and industry groups to present findings of her research. Dr. Vandenberg’s EDC-related research has been funded by US government agencies, the University of Massachusetts Amherst, and NGOs including the Cornell Douglas Foundation and the Great Neck Breast Cancer Coalition.

Dr Ivell is currently a member of the Endocrine Society’s EDC Advisory Group and is Editor-in-Chief of the specialty section ‘Reproduction’ for the journals Frontiers in Physiology and Frontiers in Endocrinology. His EDC-related research has been funded by government and academic agencies.

Dr. Zoeller has served on various advisory boards and panels of the US EPA, the NIH and Pew Charitable Trusts in relation to issues of EDCs. He is currently a member of the Endocrine Society’s EDC Advisory Group and is Co-Chair of one of its Task Force groups. His travel has been sponsored by various government, academic and industry groups to present findings of his research. Dr. Zoeller’s research has been funded by government agencies in the US and EU.
References

1. Brescia S. Thresholds of adversity and their applicability to endocrine disrupting chemicals. *Crit Rev Toxicol*. 2020;50(3):213-218.
2. Heindel J, Zoeller RT. Endocrine-Disrupting Chemicals and Human Disease. In: DeGroot LJ, Jameson JL, eds. Endocrinology: Adult and Pediatric. Vol 2: Elsevier Saunders; 2016.
3. Lanphear BP, Hornung R, Khoury J, Yolton K, Baghurst P, Bellinger DC, Canfield RL, Dietrich KN, Bornschein R, Greene T, Rothenberg SJ, Needleman HL, Schnaas L, Wasserman G, Graziano J, Roberts R. Low-level environmental lead exposure and children’s intellectual function: an international pooled analysis. *Environ Health Perspect*. 2005;113(7):894-899.
4. Vorvolakos T, Arseniou S, Samakouri M. There is no safe threshold for lead exposure: Alpha literature review. *Psychiatrike = Psychiatriki*. 2016;27(3):204-214.
5. Lanphear BP. Low-level toxicity of chemicals: No acceptable levels? *PLoS Biol*. 2017;15(12):e2003066.
6. EPA. Basic Information about Lead in Drinking Water. 2016:https://www.epa.gov/ground-water-and-drinking-water/basic-information-about-lead-drinking-water.
7. CDC. Report of the Advisory Committee on Childhood Lead Poisoning Prevention. Atlanta: Center for Disease Control and Prevention; 2012.https://www.cdc.gov/nceh/lead/ACCLPP/Final_Document_030712.pdf
8. Gee D. Late lessons from early warnings: Toward realism and precaution with endocrine-disrupting substances. *Environ Health Perspect*. 2006;114 Suppl 1:152-160.
9. Lanphear BP. The Impact of Toxins on the Developing Brain. *Annual Review of Public Health*. 2015;36(1):211-230.
10. Gore AC, Heindel JJ, Zoeller RT. Endocrine disruption for endocrinologists (and others). *Endocrinology*. 2006;147(Suppl 6):S1-3.
11. Vandenberg LN. Low dose effects challenge the evaluation of endocrine disrupting chemicals. *Trends in Food Science & Technology*. 2019;84:58-61.
12. Hill CE, Myers JP, Vandenberg LN. Nonmonotonic Dose-Response Curves Occur in Dose Ranges That Are Relevant to Regulatory Decision-Making. *Dose-response: a publication of International Hormesis Society*. 2018;16(3):1559325818798282.
13. Vandenberg LN, Colborn T, Hayes TB, Heindel JJ, Jacobs DR, Jr., Lee DH, Shioda T, Soto AM, vom Saal FS, Welshons WV, Zoeller RT, Myers JP. Hormones and endocrine-disrupting chemicals: low-dose effects and nonmonotonic dose responses. *Endocr Rev*. 2012;33(3):378-455.
14. Gore AC, Chappell VA, Fenton SE, Flaws JA, Nadal A, Prins GS, Toppari J, Zoeller RT. EDC-2: The Endocrine Society’s Second Scientific Statement on Endocrine-Disrupting Chemicals. *Endocr Rev*. 2015;36(6):E1-150.
15. Stillerman KP, Mattison DR, Giudice LC, Woodruff TJ. Environmental exposures and adverse pregnancy outcomes: a review of the science. *Reprod Sci*. 2008;15(7):631-650.
16. Rochester JR. Bisphenol A and human health: a review of the literature. *Reprod Toxicol*. 2013;42:132-155.
17. Crain DA, Janssen SJ, Edwards TM, Heindel J, Ho SM, Hunt P, Iguchi T, Juul A, McLaughlan JA, Schwartz J, Skakkebaek N, Soto AM, Swan S, Walker C, Woodruff TK, Woodruff TJ, Giudice LC, Guillette LJ, Jr. Female reproductive disorders: the roles of endocrine-disrupting compounds and developmental timing. Fertil Steril. 2008;90(4):911-940.

18. Skakkebaek NE, Rajpert-De Meyts E, Buck Louis GM, Toppari J, Andersson AM, Eisenberg ML, Jensen TK, Jorgensen N, Swan SH, Sapra KJ, Ziebe S, Priskorn L, Juul A. Male Reproductive Disorders and Fertility Trends: Influences of Environment and Genetic Susceptibility. Physiol Rev. 2016;96(1):55-97.

19. Meeker JD, Sathyanarayana S, Swan SH. Phthalates and other additives in plastics: human exposure and associated health outcomes. Philos Trans R Soc Lond B Biol Sci. 2009;364(1526):2097-2113.

20. Kahn LG, Trasande L. Environmental Toxicant Exposure and Hypertensive Disorders of Pregnancy: Recent Findings. Current hypertension reports. 2018;20(10):87.

21. Trasande L, Shaffer RM, Sathyanarayana S. Food Additives and Child Health. Pediatrics. 2018;142(2).

22. Maffini MV, Trasande L, Neltner TG. Perchlorate and Diet: Human Exposures, Risks, and Mitigation Strategies. Curr Environ Health Rep. 2016;3(2):107-117.

23. National Academies of Sciences E, Medicine. Application of Systematic Review Methods in an Overall Strategy for Evaluating Low-Dose Toxicity from Endocrine Active Chemicals. Washington, DC: The National Academies Press.

24. Demeneix B, Slama R. Endocrine Disruptors: from Scientific Evidence to Human Health Protection. Brussels: European Union; 2019. https://www.europarl.europa.eu/RegData/etudes/STUD/2019/608866/IPOL_S TU(2019)608866_EN.pdf

25. Kortenkamp A, Faust M. Regulate to reduce chemical mixture risk. Science. 2018;361(6399):224-226.

26. Bennett D, Bellinger DC, Birnbaum LS, Bradman A, Chen A, Cory-Slechta DA, Engel SM, Fallin MD, Halladay A, Hauser R, Hertz-Picciotto I, Kwiatkowski CF, Lanphear BP, Marquez E, Marty M, McPartland J, Newschaffer CJ, Payne-Sturges D, Patiasul HB, Perera FP, Ritz B, Sass J, Schantz SL, Webster TF, Whyatt RM, Woodruff TJ, Zoeller RT, Andorko L, Campbell C, Conry JA, DeNicola N, Gould RM, Hirtz D, Huffling K, Landrigan PJ, Levin A, Miller M, Mitchell MA, Rubin L, Schettler T, Tran HL, Acosta A, Brody C, Miller E, Miller P, Swanson M, Witherspoon NO. Project TENDR: Targeting Environmental Neuro-Developmental Risks The TENDR Consensus Statement. Environ Health Perspect. 2016;124(7):A118-122.

27. Hendryx M, Luo J. Children's environmental chemical exposures in the USA, NHANES 2003-2012. Environ Sci Pollut Res Int. 2018;25(6):5336-5343.

28. Solecki R, Kortenkamp A, Bergman A, Chahoud I, Degen GH, Dietrich D, Greim H, Hakansson H, Hass U, Husoy T, Jacobs M, Jobling S, Mantovan A, Marx-Stoelting P, Piersma A, Ritz V, Slama R, Stahlanman R, van den Berg M, Zoeller RT, Boobis AR. Scientific principles for the identification of endocrine-disrupting chemicals: a consensus statement. Arch Toxicol. 2017;91(2):1001-1006.

29. Ceccatelli R, Faass O, Schlumpf M, Lichtensteiger W. Gene expression and estrogen sensitivity in rat uterus after developmental exposure to the polybrominated diphenylether PBDE 99 and PCB. Toxicology. 2006;220(2-3):104-116.
30. Kleinstreuer NC, Ceger PC, Allen DG, Strickland J, Chang X, Hamm JT, Casey WM. A Curated Database of Rodent Uterotrophic Bioactivity. *Environ Health Perspect*. 2016;124(5):556-562.

31. Bergman A, Andersson AM, Becher G, van den Berg M, Blumberg B, Bjergregaard P, Bornheag CG, Bornman R, Brandt I, Brian JV, Casey SC, Fowler PA, Frouin H, Giudice LC, Iguchi T, Hass U, Jobling S, Juul A, Kidd KA, Kortenkamp A, Lind M, Martin OV, Muir D, Ochieng R, Olea N, Norrgren L, Ropstad E, Ross PS, Ruden C, Scheringer M, Skakkebaek NE, Soder O, Sonnenschein C, Soto A, Swan S, Toppari J, Tyler CR, Vandenber LN, Vinggaard AM, Wiberg K, Zoeller RT. Science and policy on endocrine disrupters must not be mixed: a reply to a "common sense" intervention by toxicology journal editors. *Environ Health*. 2013;12(1):69.

32. Kortenkamp A, Martin O, Faust M, Evans R, McKinlay R, Orton F, Rosivatz E. State of the Art Assessment of Endocrine Disruptors Final Report. Brussels: European Commission; 2011:442 pages. http://ec.europa.eu/environment/chemicals/endocrine/pdf/sota_edc_final_report.pdf

33. Zoeller RT, Brown TR, Doan LL, Gore AC, Skakkebaek NE, Soto AM, Woodruff TJ, Vom Saal FS. Endocrine-disrupting chemicals and public health protection: a statement of principles from The Endocrine Society. *Endocrinology*. 2012;153(9):4097-4110.

34. Jansen TA, Korevaar TIM, Mulder TA, White T, Muetzel RL, Peeters RP, Tiemeier H. Maternal thyroid function during pregnancy and child brain morphology: a time window-specific analysis of a prospective cohort. *The lancet Diabetes & Endocrinology*. 2019;7(8):629-637.

35. Korevaar TIM, Tiemeier H, Peeters RP. Clinical associations of maternal thyroid function with foetal brain development: Epidemiological interpretation and overview of available evidence. *Clin Endocrinol (Oxf)*. 2018.

36. Zoeller RT, Bergman A, Becher G, Bjergregaard P, Bornman R, Brandt I, Iguchi T, Jobling S, Kidd KA, Kortenkamp A, Skakkebaek NE, Toppari J, Vandenber LN. A path forward in the debate over health impacts of endocrine disrupting chemicals. *Environ Health*. 2015;14(1):118.

37. Bergman A, Hendel JJ, Jobling S, Kidd KA, Zoeller RT, eds. State of the Science of Endocrine Disrupting Chemicals 2012. Geneva, Switzerland: World Health Organization; 2013.

38. Arnold AP, Breedlove SM. Organizational and activational effects of sex steroids on brain and behavior: A reanalysis. *Hormones and Behavior*. 1985;19(4):469-498.

39. Silbergeid EK, Flaws JA, Brown KM. Organizational and activational effects of estrogenic endocrine disrupting chemicals. *Cad Saude Publica*. 2002;18(2):495-504.

40. McCarthy MM, Wright CL, Schwarz JM. New tricks by an old dogma: mechanisms of the Organizational / Activational Hypothesis of steroid-mediated sexual differentiation of brain and behavior. *Horm Behav*. 2009;55:655-665.

41. Wallen K. The Organizational Hypothesis: Reflections on the 50th anniversary of the publication of Phoenix, Goy, Gerall, and Young (1959). *Horm Behav*. 2009;55(5):561-565.

42. Patiasaul HB, Belcher SM. Endocrine disruptors, brain, and behavior. Oxford: Oxford Univ. Press.

43. Frye CA, Bo E, Calamandrei G, Calza L, Dessi-Fulgheri F, Fernandez M, Fusani L, Kah O, Kajta M, Le Page Y, Patiasaul HB, Venerosi A, Wojtowicz AK, Panzica GC. Endocrine
disrupters: a review of some sources, effects, and mechanisms of actions on
behaviour and neuroendocrine systems. J Neuroendocrinol. 2012;24(1):144-159.

44. Gore AC, Martien KM, Gagnidze K, Pfaff D. Implications of prenatal steroid
perturbations for neurodevelopment, behavior, and autism. Endocr Rev.
2014;35(6):961-991.

45. USEPA. Guidelines or Neurotoxicity Risk Assessment. Washington, D.C.: U.S.
Environmental Protection Agency; 1998.

46. Mandrup K, Boberg J, Isling LK, Christiansen S, Hass U. Low-dose effects of bisphenol
A on mammary gland development in rats. Andrology. 2016;4(4):673-683.

47. Vandenberg LN, Prins GS. Clarity in the face of confusion: new studies tip the scales
on bisphenol A (BPA). Andrology. 2016;4(4):561-564.

48. Schwarzman MR, Ackerman JM, Dairkee SH, Fenton SE, Johnson D, Navarro KM,
Osborne G, Rudel RA, Solomon GM, Zeise L, Janssen S. Screening for Chemical
Contributions to Breast Cancer Risk: A Case Study for Chemical Safety Evaluation.
Environ Health Perspect. 2015;123(12):1255-1264.

49. Rudel RA, Fenton SE, Ackerman JM, Euling SY, Makris SL. Environmental exposures
and mammary gland development: state of the science, public health implications,
and research recommendations. Environ Health Perspect. 2011;119(8):1053-1061.

50. EPA U. Integrated Risk Information Systems (IRIS) Glossary.
http://www.epa.gov/iris/help_gloss.htm: US EPA; 2012.http://www.epa.gov/iris/help_gloss.htm

51. Grandjean P, Barouki R, Bellinger DC, Casteleyn L, Chadwick LH, Cordier S, Etzel RA,
Gray KA, Ha EH, Junien C, Karagas M, Kawamoto T, Paige Lawrence B, Perera FP,
Prins GS, Puga A, Rosenfeld CS, Sherr DH, Sly PD, Suk W, Sun Q, Toppari J, van den
Hazel P, Walker CL, Heindel JJ. Life-Long Implications of Developmental Exposure to
Environmental Stressors: New Perspectives. Endocrinology. 2015;156(10):3408-3415.

52. Hessel EV, Ezendam J, van Broekhuizen FA, Hakkert B, DeWitt J, Granum G, Guzylack
L, Lawrence BP, Penninks A, Rooney AA, Piersma AH, van Loveren H. Assessment of
recent developmental immunotoxicity studies with bisphenol A in the context of the
2015 EFSA t-TDI. Reprod Toxicol. 2016;65:448-456.

53. Betancourt AM, Wang J, Jenkins S, Mobley J, Russo J, Lamartiniere CA. Altered
carcinogenesis and proteome in mammary glands of rats after prepubertal
exposures to the hormonally active chemicals bisphenol a and genistein. J Nutr.
2012;142(7):1382S-1388S.

54. Kolla S, McSweeney DB, Pokharel A, Vandenberg LN. Bisphenol S alters development
of the male mouse mammary gland and sensitizes it to a peripubertal estrogen
challenge. Toxicology. 2019;424:152234.

55. Kortenkamp A, Axelstad M, Baig AH, Bergman A, Bornehag CG, Cenijn P, Christiansen
S, Demeneix B, Derakhshan A, Fini JB, Fradrich C, Hamers T, Hellwig L, Koirle J,
Korevaar TIM, Lindberg J, Martin O, Meima ME, Mergenthaler P, Nikolov N, Du
Pasquier D, Peeters RP, Platzaek B, Ramhoj L, Remaud S, Renko K, Schole M,
Stachelscheid H, Svingen T, Wagenaars F, Wedebye EB, Zoeller RT. Removing Critical
Gaps in Chemical Test Methods by Developing New Assays for the Identification of
Thyroid Hormone System-Disrupting Chemicals-The ATHENA Project. Int J Mol Sci.
2020;21(9).

56. Mamsen LS, Björvang RD, Mucs D, Vinnars M-T, Papadogiannakis N, Lindh CH,
Andersen CY, Damdimopoulou P. Concentrations of perfluoroalkyl substances
(PFASs) in human embryonic and fetal organs from first, second, and third trimester pregnancies. *Environment International*. 2019;124:482-492.

57. Li L-X, Chen L, Meng X-Z, Chen B-H, Chen S-Q, Zhao Y, Zhao L-F, Liang Y, Zhang Y-H. Exposure Levels of Environmental Endocrine Disruptors in Mother-Newborn Pairs in China and Their Placental Transfer Characteristics. *PLOS ONE*. 2013;8(5):e62526.

58. Renwick AG, Lazarus NR. Human variability and noncancer risk assessment- An analysis of the default uncertainty factor. *Regul Toxicol Pharmacol*. 1998;27(1 Pt 2):3-20.

59. Hattis D, Baird S, Goble R. A straw man proposal for a quantitative definition of the RfD. *Drug Chem Toxicol*. 2002;25(4):403-436.

60. Salmon A, Winder B, Brown J, Riveles K. Technical support document for the derivation of noncancer reference exposure levels. *Appendix D*. 2008;1:128-169.